title: Neglected tropical diseases: survey and geometry of randomised evidence.
abstract: OBJECTIVE
  To assess the quantity and distribution of evidence from randomised controlled trials for the treatment of the major neglected tropical diseases and to identify gaps in the evidence with network analysis.
  
  
  METHODS
  Systematic review and network analysis.
  
  
  METHODS
  Cochrane Central Register of Controlled Trials and PubMed from inception to 31 August 2011.
  
  
  METHODS
  Randomised controlled trials that examined treatment of 16 neglected tropical diseases or complications thereof published in English, French, Spanish, Portuguese, German, or Dutch.
  
  
  RESULTS
  We identified 971 eligible randomised trials. Leishmaniasis (184 trials, 23,039 participants) and geohelminth infections; 160 trials, 46,887 participants) were the most studied, while dracunculiasis (nine trials, 798 participants) and Buruli ulcer (five trials, 337 participants) were least studied. Relative to its global burden of disease, lymphatic filariasis had the fewest trials and participants. Only 11% of trials were industry funded. Either a single trial or trials with fewer than 100 participants comprised the randomised evidence for first or second line treatments for Buruli ulcer, human African trypanosomiasis, American trypanosomiasis, cysticercosis, rabies, echinococcosis, New World cutaneous leishmaniasis, and each of the foodborne trematode infections. Among the 10 disease categories with more than 40 trials, five lacked sufficient head to head comparisons between first or second line treatments.
  
  
  CONCLUSIONS
  There is considerable variation in the amount of evidence from randomised controlled trials for each of the 16 major neglected tropical diseases. Even in diseases with substantial evidence, such as leishmaniasis and geohelminth infections, some recommended treatments have limited supporting data and lack head to head comparisons.
authors.affiliation: Center for Primary Care and Outcomes Research and Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Shanthi
authors.initials: S
authors.lastname: Kappagoda
authors.forename: John P A
authors.initials: JP
authors.lastname: Ioannidis
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D054312:Buruli Ulcer / Q000188:drug therapy; D003715:Dengue / Q000188:drug therapy; D004320:Dracunculiasis / Q000188:drug therapy; D004443:Echinococcosis / Q000188:drug therapy; D004605:Elephantiasis, Filarial / Q000188:drug therapy; D006373:Helminthiasis / Q000188:drug therapy; D006801:Humans; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy; D007918:Leprosy / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D058069:Neglected Diseases / Q000188:drug therapy*; D011818:Rabies / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012107:Research Design; D012109:Research Support as Topic; D012552:Schistosomiasis / Q000188:drug therapy; D013322:Strongyloidiasis / Q000188:drug therapy; D014141:Trachoma / Q000188:drug therapy; D014201:Trematode Infections / Q000188:drug therapy; D014330:Tropical Medicine; D014352:Trypanosomiasis / Q000188:drug therapy
chemical_list: D000890:Anti-Infective Agents